Vascular BioSciences Named Winner of National Institute of Health SBIR/STTR Phase I Commercialization Assistance Award for "CAR Peptide Therapeutic Adjuvant"
Vascular BioSciences was recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to develop the CAR peptide as a therapeutic adjuvant.
- Santa Barbara-Santa Maria-Goleta, CA (1888PressRelease) October 19, 2012 - CEO David Mann remarked, "The NIH SBIR/STTR Phase I Commercialization Assistance Award is a helpful step forward in commercializing our CAR peptide therapeutic adjuvant. We look forward to working with Foresight Science and Technology to develop a market entry strategy for our products."
The National Health Institute (NIH) issues a Niche Assessment Program for those that wish to stimulate commercialization. In collaboration with the NIH SBIR/STTR awardees, the Foresight Science & Technology Incorporated provides a Technology Niche Analysis that presents a company with data about market-oriented information such as market size, potential consumers, and competing technologies. Companies selected to win the award are given an in-depth, unbiased assessment of appropriate market niches for products and given opportunities to connect with potential customers, licenses, investors, or commercial partners.
About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides disease solutions in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through its majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult‒to‒treat diseases.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam